Policy & Regulation
Panorama Medicine names new executive vice president, research and preclinical development and new director
26 February 2020 -

Panorama Medicine, a genomics and computing powered drug discovery company focusing on RNA-targeted therapeutics, announced on Tuesday that it has named Jae Lee, PhD as its new executive vice president, research and preclinical development, effective 24 February and Maxine Gowen, PhD, as its director, effective 1 January 2020.

The company says that Dr Lee is an accomplished leader in drug discovery and translational research. He has around three decades of experience leading various projects of discovery and preclinical development in multiple therapeutic areas including neuroscience, immunology, cardiovascular disease, chronic kidney disease, respiratory disease and anti-infective. He joins Panorama from Kintai Therapeutics, where he was a vice president of Preclinical Development. Prior to his role at Kintai Therapeutics, Dr Lee served as the vice president of Drug Discovery Sciences at Boehringer Ingelheim Pharmaceuticals for more than 10 years. Previously, he served as senior director of DMPK at Pfizer. He started his industrial career at Novartis.

Dr Gowen is an entrepreneur, scientist, and biotech executive. She is presently the CEO of TamuroBio Inc. From 2007 until October 2018, Dr Gowen founded and served as president and chief executive officer of Trevena Inc. Prior to her long-time role at Trevena, Dr Gowen served in multiple positions of leadership at GlaxoSmithKline for fifteen years. Dr Gowen has also served in the venture capital subsidiary of GSK, SR One, as the president and managing partner, where she led investments and participated as a board member for numerous companies. Dr Gowen was vice president, Drug Discovery, Musculoskeletal Diseases at GSK until 2002 where she led drug discovery and early development of therapeutics targeted at bone diseases ranging from osteoporosis to arthritis. From 1989 to 1992, Dr Gowen held a tenured academic position in the School of Pharmacology, University of Bath, UK. Presently, Dr Gowen serves as board member for public biopharmaceutical companies Akebia Therapeutics Inc since July 2014, Idera Pharmaceuticals Inc since January 2016, and Aclaris Therapeutics Inc since July 2019. She also serves on the board of the state biotechnology industry association, Life Sciences PA and earlier held a board seat in the national biotechnology industry association, BIO, from 2008 to 2018.



Related Headlines